Seoul National University · 医学
Professor Hyun Woo Lee's research lab focuses on the intersection of environmental health, bone metabolism, and respiratory diseases. The lab investigates the long-term impacts of air pollutants like PM₂.₅ and NO₂ on chronic obstructive pulmonary disease (COPD), while also exploring molecular mechanisms regulating osteoblast and adipocyte differentiation in bone marrow. Key research directions include the role of adiponectin and berberine in osteogenesis, as well as clinical outcomes in non-small cell lung cancer (NSCLC) and sepsis management. The lab integrates molecular signaling, transcriptional regulation, and clinical epidemiology to identify therapeutic targets for metabolic and respiratory disorders.
Figures are computed from collected data and may differ slightly.
Long-term exposure to PM<sub>2.5</sub> and NO<sub>2</sub> can be associated with increased incidence of COPD.
In bone marrow, osteoblasts and adipocytes are differentiated from mesenchymal progenitor cells and their differentiation is reciprocally regulated by largely unknown mechanisms. In this study, we investigated downstream signaling cascades of adiponectin, a member of the adipocytokine family, in the regulation of osteoblast differentiation. Adiponectin augmented expression of several osteogenic marker genes and increased osteoblast differentiation in mesenchymal progenitor cells. The expression
Berberine (BBR) has been implicated in bone biology. Although BBR reduces osteoporosis by enhancing BMD and inhibiting osteoclast activity, the effects of BBR on osteoblasts during the process of osteogenesis have not been thoroughly studied. In osteoblastic cells, BBR enhanced the expression of osteogenic marker genes including osteopontin and osteocalcin and promoted the transcriptional activity of the key osteogenic transcription factor Runx2. In osteoblasts, BBR increased the binding of Runx
Stage I-III NSCLC located in the upper lobes showed higher five-year survival rates compared to other tumor locations.
These findings suggest that triple therapy can potentially be the best option for stable COPD patients in terms of reducing exacerbation and all-cause mortality.
Pre-hospitalization use of ACE inhibitors or ARBs for sepsis was an independent factor for a lower rate of in-hospital mortality.
The development of pneumonia delayed viral clearance in patients with mild COVID-19. Elderly patients or those suffering from diarrhea should be closely monitored, given the increased risk of developing pneumonia.
In patients with ARDS, a low serum uric acid level may be a prognostic marker of a low risk of in-hospital mortality.
It is controversial whether a tumor located in the lower lobe is related with worse outcome of non-small cell lung cancer (NSCLC). This study aimed to clarify the prognostic role of primary tumor location in NSCLC. Patients newly diagnosed with NSCLC in a tertiary referral hospital from January 2011 to December 2014 were followed up for 5 years. Of the 2,289 NSCLC cases, 911 (39.8%) cases pertained to lower lobe cancers. Patients with lower lobe cancer showed a higher all-cause mortality rate th
ACEI/ARB therapy was not associated with increased risk of all-cause mortality or severe manifestations in patients with COVID-19. ACEI/ARB therapy can be continued without concern of drug-related worsening in patients with COVID-19.
Early bronchoscopy could benefit the clinical outcomes of mechanically ventilated patients with aspiration pneumonia.
Our findings suggest that long-term exposure to PM10 is associated with lung cancer development. A novel approach to lung cancer screening needs to be considered depending on the exposed PM10 level.
Open papers in the app to read, cite, and organize with AI.
